$DSGN News

Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1

Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability Score

Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21

Design Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript

Design Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.

Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate

Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15

RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14

Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate

Design Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $18 price target.

Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18

Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14

Design Therapeutics to Participate in Upcoming Investor Conferences